Recent data shows that krill powder is effective in reducing atherosclerosis in mice
Rimfrost, in collaboration with partners in New Zealand, has developed and patented a krill powder for human nutraceutical applications.
In a long-term collaboration with the University in Bergen, with the financial support from the Norwegian Research Council, krill products have been tested in animal models and in humans and the results have been published in international scientific journals.
The most recent data shows that krill powder is effective in reducing atherosclerosis in apo E-/- mice, suggesting that it also may be effective in improving vascular health in humans.
Rimfrost and University of Bergen published an article Last year showing that in rats krill powder was effective in reducing plasma triglycerides, plasma cholesterol as well as inflammation marker Interleukin-2.
In healthy humans, it was observed to reduce plasma triglycerides, VLDL and chylomicron concentrations, accompanied by increased plasma antioxidant capacity and anti-inflammatory properties.
The major feature of atherosclerosis is the interaction between lipids and inflammation, hence krill powder was tested in animal model for atherosclerosis.
'The results we have obtained using apo E-/- mice are highly intriguing. Krill powder modulates risk factors related to atherosclerotic disorders by acting both at vascular and systemic levels. A significant reduction in the atherosclerotic plaque in the aortic arch, thoracic and abdominal aorta is obtained,' Says Professor Rolf K Berge, University of Bergen, Norway.